---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-118344"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:23:46.737204+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion reports Q3 net loss of $32.8M; FDA lifts clinical hold on diabetes trials

## Summary
- Cash and cash equivalents $88.3M as of Sep 30, 2024, down from $177.2M at Dec 31, 2023.
- Net loss $32.8M for Q3 2024 vs $28.4M same period 2023; includes $4.7M stock-based comp.
- FDA lifted clinical hold on COVALENT-111 (type 2 diabetes) and COVALENT-112 (type 1 diabetes) trials.
- Topline Week 26 data for both trials expected in December 2024.
- Announced third clinical candidate BMF-650 (oral GLP-1 RA); preclinical data to be shared Oct 30.

## SEC filing metadata
- accession: 0000950170-24-118344
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017024118344/0000950170-24-118344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017024118344/bmea-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-118344
- JSON: https://secwatch.observer/filing/0000950170-24-118344.json
- Plain text: https://secwatch.observer/filing/0000950170-24-118344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.